By restoring beta cell mass in the diabetic’s pancreas is the curative approach for a comprehensive strategy to effectively manage a patient’s blood glucose level: not only through reacting to glucose increase with supplemental insulin, but also coordinating with its endogenous synergistic partner amylin release to slow the glucose release into the blood. Therefore, we are developing a first-in-class curative diabetes drug called Menin inhibitor, a small molecule that will stimulate the insulin producing beta-cells in the pancreatic islet to regenerate.

It is estimated that 1 in 10 Americans currently have Type 2 Diabetes (T2D), costing $174 billion per year on diabetes associated expenses. If this trend continues, 1 in 3 Americans will suffer from T2D by the year 2050. T2D accounts for over 90% of all diabetes and the 7 major markets. Our mission is to respond to dire need for new and innovative therapeutics against diabetes in order to reduce the patient suffering and cost of healthcare.